PharmCube has just released its 2026 list of 100 New Targets to Watch. This year’s compendium highlights a significant shift in global R&D:
• Oncology Dominance: 50% of targets are focused on cancer, with major breakthroughs in immunotherapy and CAR-T (e.g., VDAC2, SERT, and AOAH).
• Neurodegenerative Advances: Critical new leads for Alzheimer’s and Parkinson’s (e.g., FAM171A2, TIM-3).
• Metabolic Frontiers: New pathways for Obesity, MASH, and Type 2 Diabetes (e.g., ALKBH5).

🌟 Key Highlight for 2026: Over half of these targets were discovered by Chinese scientist teams, with findings published in Cell, Nature, and Science. This underscores the rapidly growing influence of China in source innovation.

Featured Milestone Targets included in the report:
📍 PELO: A promising synthetic lethality target for specific cancers.
📍 CGRP: A potential "short-circuit" for gastric cancer neural circuits.
📍 FAM171A2: A world-first target for early-stage Parkinson’s intervention.
📍 GLUD1: Overcoming immunotherapy resistance by targeting ammonia metabolism.